EL-08
Written by the Elevate Clinical Team
Inflammation and immune symptoms can have many underlying causes. Evaluation focuses on the individual history rather than assuming that an immune-focused therapy is appropriate.
5 therapies
EL-03 · Recovery & Repair / EL-08 · Immune & Inflammation
Injection
$299 / month
2 mg/mL · 5 mL vial
PCAC's July 2026 recommendation is advisory, not final; this substance remains off the 503A list. HHS/FDA announced an interim enforcement discretion policy on October 28, subject to the conditions set out in that policy. It is not FDA approval and does not apply to research-use-only products. We are confirming pharmacy compliance before changing what we dispense. Current FDA / PCAC status.
EL-03 · Recovery & Repair / EL-08 · Immune & Inflammation
Cream
$319 / month
2 mg/mL · 30 g
PCAC's July 2026 recommendation is advisory, not final; this substance remains off the 503A list. HHS/FDA announced an interim enforcement discretion policy on October 28, subject to the conditions set out in that policy. It is not FDA approval and does not apply to research-use-only products. We are confirming pharmacy compliance before changing what we dispense. Current FDA / PCAC status.
EL-08 · Immune & Inflammation
Nasal
$249 / month
5mcg/0.1ml · 0.1 mL
EL-08 · Immune & Inflammation
Injection
$349 / month
3,000 mcg/mL · 5 mL vial
EL-08 · Immune & Inflammation
Nasal
$379 / month
150 mcg per 0.1 mL spray
KPV and thymosin alpha-1 are different substances, not interchangeable options. The clinical team reviews their evidence, suitability and formulation before prescribing.
A treatment plan also includes instructions, monitoring and a review of changes in health or medications. Questions about suitability or administration belong with the clinical team.
Written by the Elevate Clinical Team